Background/Aims: KLOTHO, a type-1 transmembrane protein with glucurodinase activity, is expressed in tissues responsible for calcium homeostasis such as the kidney, parathyroid gland and the epithelium of the choroid plexus in the brain. Given the emerging evidence indicating a novel regulatory function for KLOTHO protein in renal calcium and phosphate homeostasis, the present study aims to investigate the association between KLOTHO genetic polymorphisms and kidney stone (KS). Methods:KLOTHO gene polymorphisms G395A in the promoter region, F252V in exon 2, and C1818T in exon 4 were investigated in 108 patients with renal calcium stone formation and 51 age-matched healthy volunteers with no history of renal stone formation, using polymerase chain reaction. Results: GG genotype of G395A KLOTHO polymorphism had approximately 2-fold increased KS risk compared with the homozygous genotype AA and heterozygote GA (OR 1.849, 95% CI 1.016–3.364, p = 0.044). We also found that non-A allele carriers had significantly higher KS risk associated with the KS clinical characteristics including hypercalcemia, hypophosphatemia and phosphaturia. Conclusion: Our findings suggested that the G395A polymorphism of KLOTHO gene is associated with the KSs and may act as a risk factor for the development of KS disease.

Keywords:
KLOTHO, G395A, Kidney stone, F252V, C1818T
1.
Pak CY: Kidney stones. Lancet 1998;351:1797–1801.
2.
Prie D, Ravery V, Boccon-Gibod L, Friedlander G: Frequency of renal phosphate leak among patients with calcium nephrolithiasis. Kidney Int 2001;60:272–276.
3.
Worcester EM, Coe FL: New insights into the pathogenesis of idiopathic hypercalciuria. Semin Nephrol 2008;28:120–132.
4.
Fleet JC, Eksir F, Hance KW, Wood RJ: Vitamin D-inducible calcium transport and gene expression in three Caco-2 cell lines. Am J Physiol Gastrointest Liver Physiol 2002;283:G618–G625.
5.
Song Y, Peng X, Porta A, Takanaga H, Peng JB, Hediger MA, Fleet JC, Christakos S: Calcium transporter-1 and epithelial calcium channel messenger ribonucleic acid are differentially regulated by 1,25-dihydroxyvitamin D3 in the intestine and kidney of mice. Endocrinology 2003;144:3885–3894.
6.
Taylor JG, Bushinsky DA: Calcium and phosphorus homeostasis. Blood Purif 2009;27:387–394.
7.
Katai K, Miyamoto K, Kishida S, Segawa H, Nii T, Tanaka H, Tani Y, Arai H, Tatsumi S, Morita K, Taketani Y, Takeda E: Regulation of intestinal Na+-dependent phosphate co-transporters by a low-phosphate diet and 1,25-dihydroxyvitamin D3. Biochem J 1999;343:705–712.
8.
Razzaque MS, Lanske B: The emerging role of the fibroblast growth factor-23-Klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 2007;194:1–10.
9.
Matsumura Y, Aizawa H, Shiraki-Iida T, Nagai R, Kuro-o M, Nabeshima Y: Identification of the human Klotho gene and its two transcripts encoding membrane and secreted Klotho protein. Biochem Biophys Res Commun 1998;242:626–630.
10.
Chen CD, Podvin S, Gillespie E, Leeman SE, Abraham CR: Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci USA 2007;104:19796–19801.
11.
Chang Q, Hoefs S, van der Kemp AW, Topala CN, Bindels RJ, Hoenderop JG: The β-glucuronidase Klotho hydrolyzes and activates the TRPV5 channel. Science 2005;310:490–493.
12.
Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M: Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 2006;281:6120–6123.
13.
Hu MC, Shi M, Zhang J, Pastor J, Nakatani T, Lanske B, Shawkat Razzaque M, Rosenblatt KP, Baum MG, Kuro OM, Moe OW: Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010;24:3438–3450.
14.
Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45–51.
15.
Kuro-o M: Klotho and aging. Biochim Biophys Acta 2009;1790:1049–1058.
16.
Riancho JA, Valero C, Hernandez JL, Ortiz F, Zarrabeitia A, Alonso MA, Pena N, Pascual MA, Gonzalez-Macias J, Zarrabeitia MT: Association of the F352V variant of the Klotho gene with bone mineral density. Biogerontology 2007;8:121–127.
17.
Shimoyama Y, Nishio K, Hamajima N, Niwa T: Klotho gene polymorphisms G395A and C1818T are associated with lipid and glucose metabolism, bone mineral density and systolic blood pressure in Japanese healthy subjects. Clin Chim Acta 2009;406:134–138.
18.
Yamada Y, Ando F, Niino N, Shimokata H: Association of polymorphisms of the androgen receptor and Klotho genes with bone mineral density in Japanese women. J Mol Med 2005;83:50–57.
19.
Pietschmann F, Breslau NA, Pak CY: Reduced vertebral bone density in hypercalciuric nephrolithiasis. J Bone Miner Res 1992;7:1383–1388.
20.
Caudarella R, Vescini F, Buffa A, Sinicropi G, Rizzoli E, La Manna G, Stefoni S: Bone mass loss in calcium stone disease: focus on hypercalciuria and metabolic factors. J Nephrol 2003;16:260–266.
21.
Huang CL: Regulation of ion channels by secreted Klotho: mechanisms and implications. Kidney Int 2010;77:855–860.
22.
Low AF, O’Donnell CJ, Kathiresan S, Everett B, Chae CU, Shaw SY, Ellinor PT, MacRae CA: Aging syndrome genes and premature coronary artery disease. BMC Med Genet 2005;6:38.
23.
Kawano K, Ogata N, Chiano M, Molloy H, Kleyn P, Spector TD, Uchida M, Hosoi T, Suzuki T, Orimo H, Inoue S, Nabeshima Y, Nakamura K, Kuro-o M, Kawaguchi H: Klotho gene polymorphisms associated with bone density of aged postmenopausal women. J Bone Miner Res 2002;17:1744–1751.
24.
Arking DE, Krebsova A, Macek M Sr, Macek M Jr, Arking A, Mian IS, Fried L, Hamosh A, Dey S, McIntosh I, Dietz HC: Association of human aging with a functional variant of Klotho. Proc Natl Acad Sci USA 2002;99:856–861.
25.
Lu P, Boros S, Chang Q, Bindels RJ, Hoenderop JG: The β-glucuronidase Klotho exclusively activates the epithelial Ca2+ channels TRPV5 and TRPV6. Nephrol Dial Transplant 2008;23:3397–3402.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.